NO313125B1 - Farmasöytiske formuleringer inneholdende vorikonazol - Google Patents
Farmasöytiske formuleringer inneholdende vorikonazol Download PDFInfo
- Publication number
- NO313125B1 NO313125B1 NO19995565A NO995565A NO313125B1 NO 313125 B1 NO313125 B1 NO 313125B1 NO 19995565 A NO19995565 A NO 19995565A NO 995565 A NO995565 A NO 995565A NO 313125 B1 NO313125 B1 NO 313125B1
- Authority
- NO
- Norway
- Prior art keywords
- voriconazole
- formulation according
- cyclodextrin
- formula
- cyclodextrin derivative
- Prior art date
Links
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 title claims description 15
- 229960004740 voriconazole Drugs 0.000 title claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 12
- -1 alkali metal salt Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical group OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- BCEHBSKCWLPMDN-HWPZZCPQSA-N (2s,3r)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol Chemical compound C1([C@@H](C)[C@@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-HWPZZCPQSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9713149.4A GB9713149D0 (en) | 1997-06-21 | 1997-06-21 | Pharmaceutical formulations |
| PCT/EP1998/003477 WO1998058677A1 (fr) | 1997-06-21 | 1998-06-02 | Formulations pharmaceutiques contenant du voriconazole |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995565D0 NO995565D0 (no) | 1999-11-12 |
| NO995565L NO995565L (no) | 1999-11-30 |
| NO313125B1 true NO313125B1 (no) | 2002-08-19 |
Family
ID=10814734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995565A NO313125B1 (no) | 1997-06-21 | 1999-11-12 | Farmasöytiske formuleringer inneholdende vorikonazol |
Country Status (48)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818258D0 (en) * | 1998-08-21 | 1998-10-14 | Pfizer Ltd | Antifungal compositions |
| PE20020300A1 (es) | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
| AR031135A1 (es) | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| BR0313602A (pt) * | 2002-08-20 | 2005-06-21 | Bristol Myers Squibb Co | Método e formulação de complexo de aripiprazol |
| GB0327390D0 (en) * | 2003-11-25 | 2003-12-31 | Pfizer Ltd | Pharmaceutical formulations |
| CA2548491A1 (fr) * | 2003-12-08 | 2005-06-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions anticancereuses synergiques |
| CA2572223C (fr) | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Inhibiteurs d'angiogenese |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| WO2007047253A2 (fr) * | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Formulations pharmaceutiques de cyclodextrines et composes antifongiques de type azole |
| AR061889A1 (es) | 2006-07-13 | 2008-10-01 | Medichem Sa | Proceso mejorado para la preparacion de voriconazol |
| CN1919846B (zh) * | 2006-09-14 | 2013-01-02 | 大道隆达（北京）医药科技发展有限公司 | 伏立康唑及其药用盐、中间体的一种新定向合成制备方法 |
| BG1110U1 (bg) * | 2007-06-19 | 2008-09-30 | Рудолф ПОДЛИПСКИ | Отоплителен съд за експресно локално загряване навода |
| EP2018866A1 (fr) * | 2007-07-27 | 2009-01-28 | Sandoz AG | Compositions pharmaceutiques contenant du voriconazole |
| US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
| WO2009137611A2 (fr) * | 2008-05-06 | 2009-11-12 | Board Of Regents, The University Of Texas System | Traitement d’infection fongique pulmonaire avec du voriconazole et par inhalation |
| WO2010084505A2 (fr) * | 2008-06-06 | 2010-07-29 | Glenmark Pharmaceuticals Limited | Formulation topique stable comprenant du voriconazole |
| CN101390825B (zh) * | 2008-10-01 | 2010-12-29 | 山东省眼科研究所 | 一种伏立康唑眼内释药系统 |
| CA2741312C (fr) | 2008-10-21 | 2020-10-27 | Onyx Therapeutics, Inc. | Therapie de combinaison avec des peptides epoxycetones |
| CN101444510B (zh) * | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 含有伏立康唑的药物制剂及其制备方法 |
| ES2573982T3 (es) | 2009-08-19 | 2016-06-13 | Ratiopharm Gmbh | Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina |
| WO2011064558A2 (fr) | 2009-11-30 | 2011-06-03 | Cipla Limited | Composition pharmaceutique |
| MX338685B (es) | 2010-06-29 | 2016-04-26 | Merck Sharp & Dohme | Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida. |
| EP2409699B1 (fr) | 2010-07-23 | 2014-04-30 | Combino Pharm, S.L. | Compositions stables de voriconazole |
| CN102058519B (zh) * | 2010-11-19 | 2013-01-02 | 苏州特瑞药业有限公司 | 一种伏立康唑缓释栓剂及其制备方法 |
| RU2566262C2 (ru) | 2011-06-15 | 2015-10-20 | Синтон Бв | Стабилизированная композиция вориконазола |
| EP2561863A1 (fr) | 2011-08-22 | 2013-02-27 | Farmaprojects, S.A.U. | Compositions pharmaceutiques comportant du voriconazole |
| EP2874640A4 (fr) * | 2012-01-05 | 2016-10-26 | Frederick Timothy Guilford | Glutathione réduite encapsulée dans un liposome pour le traitement du cancer, y compris en combinaison avec d'autres compositions pharmaceutiques |
| US8853248B2 (en) | 2012-04-05 | 2014-10-07 | Hubert Maehr | (1,2,3-triazolyl)sulfonyl derivatives |
| KR20190137963A (ko) | 2012-05-08 | 2019-12-11 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
| CN104519867A (zh) | 2012-05-11 | 2015-04-15 | 希普拉有限公司 | 药物组合物 |
| AU2014204878B2 (en) | 2013-01-11 | 2018-04-19 | Xellia Pharmaceuticals Aps | Voriconazole inclusion complexes |
| EP2968595A2 (fr) | 2013-03-14 | 2016-01-20 | Fresenius Kabi USA LLC | Formulations de voriconazole |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| CN103690968A (zh) * | 2013-11-21 | 2014-04-02 | 石药集团中奇制药技术（石家庄）有限公司 | 一种伏立康唑组合物及其制备方法 |
| PT109117B (pt) * | 2016-01-28 | 2019-02-01 | Hovione Farm Sa | Complexação de ingredientes ativos farmacêuticos |
| EP3541364A1 (fr) | 2016-11-18 | 2019-09-25 | AiCuris Anti-infective Cures GmbH | Nouvelles formulations de composés de la famille des bêta-lactamines substitués par une amidine, à base de cyclodextrines modifiées et d'agents acidifiants, leur préparation et leur utilisation en tant que compositions pharmaceutiques antimicrobiennes |
| CN108456194B (zh) * | 2017-02-17 | 2021-06-22 | 武汉朗来科技发展有限公司 | 三氮唑抗菌衍生物、其药物组合物和用途 |
| CN113750034A (zh) * | 2020-06-05 | 2021-12-07 | 中南大学湘雅三医院 | 耳用温敏凝胶及其制备方法 |
| CN116570558B (zh) * | 2023-06-21 | 2023-12-26 | 广州仁恒医药科技股份有限公司 | 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| DE3347421A1 (de) | 1983-12-29 | 1985-07-11 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen |
| GB8819308D0 (en) | 1988-08-13 | 1988-09-14 | Pfizer Ltd | Triazole antifungal agents |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9002375D0 (en) * | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
| US5278175A (en) * | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| GB9512961D0 (en) | 1995-06-26 | 1995-08-30 | Pfizer Ltd | Antifungal agents |
| GB9602080D0 (en) | 1996-02-02 | 1996-04-03 | Pfizer Ltd | Pharmaceutical compounds |
-
1997
- 1997-06-21 GB GBGB9713149.4A patent/GB9713149D0/en active Pending
-
1998
- 1998-02-06 UA UA99126910A patent/UA57083C2/uk unknown
- 1998-05-05 TW TW087106918A patent/TW406023B/zh not_active IP Right Cessation
- 1998-06-02 TR TR1999/03191T patent/TR199903191T2/xx unknown
- 1998-06-02 AU AU81104/98A patent/AU724799B2/en not_active Expired
- 1998-06-02 DK DK98930793T patent/DK1001813T3/da active
- 1998-06-02 SK SK1593-99A patent/SK282946B6/sk not_active IP Right Cessation
- 1998-06-02 CN CN98806446A patent/CN1125653C/zh not_active Expired - Lifetime
- 1998-06-02 ME MEP-1999-681A patent/ME00907B/me unknown
- 1998-06-02 EP EP98930793.9A patent/EP1001813B8/fr not_active Expired - Lifetime
- 1998-06-02 US US09/402,289 patent/US6632803B1/en not_active Expired - Lifetime
- 1998-06-02 ID IDW991429A patent/ID22939A/id unknown
- 1998-06-02 RS YUP-681/99A patent/RS49633B/sr unknown
- 1998-06-02 KR KR10-1999-7012034A patent/KR100372988B1/ko not_active IP Right Cessation
- 1998-06-02 PT PT98930793T patent/PT1001813E/pt unknown
- 1998-06-02 EA EA199900937A patent/EA001924B1/ru not_active IP Right Cessation
- 1998-06-02 WO PCT/EP1998/003477 patent/WO1998058677A1/fr active IP Right Grant
- 1998-06-02 CZ CZ19994096A patent/CZ289570B6/cs not_active IP Right Cessation
- 1998-06-02 NZ NZ501066A patent/NZ501066A/xx not_active IP Right Cessation
- 1998-06-02 IL IL13291898A patent/IL132918A/en not_active IP Right Cessation
- 1998-06-02 DE DE69814091T patent/DE69814091T2/de not_active Expired - Lifetime
- 1998-06-02 PL PL337692A patent/PL191295B1/pl unknown
- 1998-06-02 BR BRPI9809468A patent/BRPI9809468B8/pt active IP Right Grant
- 1998-06-02 HU HU0003323A patent/HU228338B1/hu unknown
- 1998-06-02 AT AT98930793T patent/ATE238812T1/de active
- 1998-06-02 JP JP11503686A patent/JP2000513029A/ja not_active Withdrawn
- 1998-06-02 ES ES98930793T patent/ES2195355T3/es not_active Expired - Lifetime
- 1998-06-02 CA CA002295035A patent/CA2295035C/fr not_active Expired - Lifetime
- 1998-06-02 SI SI9830469T patent/SI1001813T1/xx unknown
- 1998-06-10 PA PA19988453201A patent/PA8453201A1/es unknown
- 1998-06-15 SA SA98190159A patent/SA98190159B1/ar unknown
- 1998-06-17 MA MA25117A patent/MA26508A1/fr unknown
- 1998-06-17 TN TNTNSN98090A patent/TNSN98090A1/fr unknown
- 1998-06-17 DZ DZ980133A patent/DZ2523A1/fr active
- 1998-06-18 AP APAP/P/1998/001268A patent/AP912A/en active
- 1998-06-18 AR ARP980102924A patent/AR015900A1/es active IP Right Grant
- 1998-06-19 ZA ZA9805364A patent/ZA985364B/xx unknown
- 1998-06-19 PE PE1998000539A patent/PE84899A1/es not_active IP Right Cessation
- 1998-06-19 HR HR980341A patent/HRP980341B1/xx not_active IP Right Cessation
- 1998-06-19 UY UY25055A patent/UY25055A1/es not_active IP Right Cessation
- 1998-06-20 EG EG70998A patent/EG23910A/xx active
- 1998-06-20 MY MYPI98002792A patent/MY118151A/en unknown
- 1998-06-23 CO CO98035641A patent/CO4940450A1/es unknown
-
1999
- 1999-11-12 NO NO19995565A patent/NO313125B1/no not_active IP Right Cessation
- 1999-11-15 BG BG103882A patent/BG64584B1/bg unknown
- 1999-11-15 IS IS5248A patent/IS2004B/is unknown
- 1999-12-10 OA OA9900277A patent/OA11232A/en unknown
-
2000
- 2000-11-17 HK HK00107329A patent/HK1027966A1/xx not_active IP Right Cessation
-
2002
- 2002-03-27 JP JP2002088076A patent/JP5089004B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313125B1 (no) | Farmasöytiske formuleringer inneholdende vorikonazol | |
| US6133248A (en) | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof | |
| RU2099354C1 (ru) | Очищенное производное циклодекстрина, клатратный комплекс очищенного производного циклодекстрина с лекарственным средством, фармацевтическая композиция | |
| AU565966B2 (en) | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation | |
| KR100279111B1 (ko) | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 | |
| KR20040106452A (ko) | 아미오다론 및 설포알킬 에테르 사이클로덱스트린을함유하는 제제 | |
| JPH0336827B2 (fr) | ||
| EP0435682A2 (fr) | Utilisation de complexes d'inclusion des prostaglandines avec des cyclodextrines dans le traitement de l'hypertension oculaire | |
| CA2204451C (fr) | Procede de selection d'un sel servant a la preparation d'un complexe d'inclusion | |
| WO1996032135A1 (fr) | Composition pharmaceutique | |
| KR20220123388A (ko) | 알킬화된 사이클로덱스트린 조성물 및 이의 제조 및 사용 방법 | |
| WO1996041646A2 (fr) | Compositions pharmaceutiques contenant du lornoxicam et de la cyclodextrine | |
| MXPA99012075A (en) | Pharmaceutical formulations containing voriconazole | |
| KR20040091004A (ko) | 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |